Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.

Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Abstract Text:

Walter P Carney,

Pharmaceutical companies have developed targeted therapies such as trastuzumab and lapatinib for human epidermal growth factor receptor (HER)2/neu-positive tumors, while others have developed antiepidermal growth factor receptor (EGFR) therapies, such as tarceva and erbitux for EGFR-positive tumors. A drug called rencarex is targeted to an oncoprotein designated carbonic anhydrase IX (CAIX), which is being evaluated in renal cell carcinoma patients. Based on these targeted therapeutic approaches, this review describes clinical research studies performed with enzyme-linked immunosorbent assays specific for the circulating oncoproteins, HER2/neu, EGFR and CAIX. These circulating biomarkers have the potential to be used in conjunction with the specific targeted therapies for patient selection, monitoring and management. With the variety of new therapeutic options, the major challenge ahead will be to select the appropriate therapy or combinations of therapies for each patient. Specific biomarker tests, either alone or in panels, will be needed at the appropriate time in the course of disease to ensure that patients receive the right drug at the right time. These tests will also be valuable in monitoring the efficacy of the targeted therapies. A circulating biomarker such as serum HER2/neu may be able to specifically identify patients with progressing HER2/neu-positive disease and provide the information needed by physicians to choose from the variety of HER2/neu-targeted therapies that will soon be available to cancer patients.

Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Publishing Authors By Initials

WP Carney,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Journal Published:

PUBLICATION TYPE: Review

Journal: Expert review of molecular diagnostics

VOLUME: 7

Page Numbers: 309-19

Journal Abbreviation: Expert Rev. Mol. Diagn.

ISSN: 1744-8352

DAY: 10

MONTH: May

YEAR: 2007

Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Information

Number of References: 60

LANGUAGE: eng

NlmUniqueID: 101120777

Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.

AFFILIATION: Oncogene Science, Siemens Medical Solutions Diagnostics, Cambridge, MA 02142, USA. walter.carney@siemens.com

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Expert Rev Mol Diagn

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Circulating oncoproteins HER2/neu, EGFR and CAIX MN as novel cancer biomarkers Related Publications

• A multinomial model for identifying significant pure-tone threshold shifts.
• Autocorrelation artifacts in optical coherence tomography and interferometric synthetic aperture microscopy.
• Breast cancer risk factors in relation to breast density (United States).
• Breast density in relation to risk of ductal carcinoma in situ of the breast in women undergoing screening mammography.
• Changes in regional cerebral blood flow following mood challenge in drug-free, remitted patients with unipolar depression.
• Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.
• Clinical implications of the biology of small cell lung cancer.
• Cues for masked amplitude-modulation detection.
• Determination of the potential benefit of time-frequency gain manipulation.
• Developmental effects of multiple looks in speech sound discrimination.
• Dimerization of the Rad50 protein is independent of the conserved hook domain.
• Does skeletal maturity predict sequential contralateral involvement after fixation of slipped capital femoral epiphysis?
• Dose-response effects of cognitive-behavioral insomnia therapy: a randomized clinical trial.
• Effects of acute hippocampal stimulation on EEG dynamics.
• Hyalinizing trabecular carcinoma of the thyroid gland.
• Inflammatory ringworm due to Trichophyton faviforme; report of 17 cases.
• Inverse scattering for frequency-scanned full-field optical coherence tomography.
• Localizing sites of activation in primary visual cortex using visual-evoked potentials and functional magnetic resonance imaging.
• Non-parametric early seizure detection in an animal model of temporal lobe epilepsy.
• Nonparaxial vector-field modeling of optical coherence tomography and interferometric synthetic aperture microscopy.
• Optically active compounds related to methadon.
• Ovarian cancer hormonal and environmental risk effect.
• Palmar bypass for digital ischemia.
• Perfluorooctylbromide as a contrast agent for CT and sonography: preliminary clinical results.
• Poverty and crime in southern California.
• Pulmonary chondroma: a tumor associated with Carney triad and different from pulmonary hamartoma.
• Spectral self-interference microscopy for low-signal nanoscale axial imaging.
• Temporal measures and neural strategies for detection of tones in noise based on responses in anteroventral cochlear nucleus.
• The AIDS patient and the last ICU bed: scarcity, medical futility, and ethics.
• Treatment of mild hypertension.